Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.
about
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.Venous thromboembolism and malignancy.Interaction of warfarin with drugs, natural substances, and foods.Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteersClinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.Brand name versus generic warfarin: a systematic review of the literature.The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.The association of proton pump inhibitors and hypomagnesemia in the community setting.Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up.Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery.
P2860
Q33506237-54A1266D-8AB8-4291-9E01-00FCB87BA951Q35728779-7CDC3559-A965-4FCA-876B-E35EDCC3DECFQ36007599-1E6F06AF-D3C1-45D9-864A-7059A85E3A54Q37053912-4883FA78-D138-4A96-9C1F-83B90584887BQ37269872-E9C46CB2-3FE5-4992-A79E-9261194E7FDBQ37859367-C58CEC49-2DB7-4F98-BC7D-64A0BD2E9128Q38532357-1D96FF37-B92B-4D0A-9A3B-21544EB2DB89Q40597366-D536738B-95E5-4833-B987-7C8A9D4E9913Q43698781-6988F66D-8549-4144-964E-25E09DB629B0Q44104361-35897FD4-6E8B-418D-B18C-D4725BDAACB8Q48119796-43B7525E-FE44-4D8A-8C0B-94AEA1DDDA1AQ53567303-4F35748A-B1FF-4D73-ACDE-8278E66A8608Q55129512-1B9D9A55-AAC7-43AB-ADAC-927CD83129E2
P2860
Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Increased warfarin doses and d ...... nationwide generic switching.
@en
Increased warfarin doses and d ...... nationwide generic switching.
@nl
type
label
Increased warfarin doses and d ...... nationwide generic switching.
@en
Increased warfarin doses and d ...... nationwide generic switching.
@nl
prefLabel
Increased warfarin doses and d ...... nationwide generic switching.
@en
Increased warfarin doses and d ...... nationwide generic switching.
@nl
P2093
P1476
Increased warfarin doses and d ...... nationwide generic switching.
@en
P2093
Daniel Kurnik
Ehud Kokia
Hillel Halkin
Jonathan Shapiro
Ronen Loebstein
Varda Shalev
P304
P356
10.1016/S0009-9236(03)00166-8
P407
P577
2003-09-01T00:00:00Z